Cargando…
Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral respons...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281508/ https://www.ncbi.nlm.nih.gov/pubmed/35472242 http://dx.doi.org/10.1182/blood.2022016166 |
_version_ | 1784746896630218752 |
---|---|
author | Oh, Bernice Ling Zhi Tan, Nicole de Alwis, Ruklanthi Kunasegaran, Kamini Chen, Zhiwei Poon, Michelle Chan, Esther Low, Jenny G. H. Yeoh, Allen Eng Juh Bertoletti, Antonio Le Bert, Nina |
author_facet | Oh, Bernice Ling Zhi Tan, Nicole de Alwis, Ruklanthi Kunasegaran, Kamini Chen, Zhiwei Poon, Michelle Chan, Esther Low, Jenny G. H. Yeoh, Allen Eng Juh Bertoletti, Antonio Le Bert, Nina |
author_sort | Oh, Bernice Ling Zhi |
collection | PubMed |
description | Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia. |
format | Online Article Text |
id | pubmed-9281508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-92815082022-07-15 Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients Oh, Bernice Ling Zhi Tan, Nicole de Alwis, Ruklanthi Kunasegaran, Kamini Chen, Zhiwei Poon, Michelle Chan, Esther Low, Jenny G. H. Yeoh, Allen Eng Juh Bertoletti, Antonio Le Bert, Nina Blood Letters to Blood Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia. American Society of Hematology 2022-07-14 /pmc/articles/PMC9281508/ /pubmed/35472242 http://dx.doi.org/10.1182/blood.2022016166 Text en © 2022 by The American Society of Hematology |
spellingShingle | Letters to Blood Oh, Bernice Ling Zhi Tan, Nicole de Alwis, Ruklanthi Kunasegaran, Kamini Chen, Zhiwei Poon, Michelle Chan, Esther Low, Jenny G. H. Yeoh, Allen Eng Juh Bertoletti, Antonio Le Bert, Nina Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients |
title | Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients |
title_full | Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients |
title_fullStr | Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients |
title_full_unstemmed | Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients |
title_short | Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients |
title_sort | enhanced bnt162b2 vaccine-induced cellular immunity in anti-cd19 car t cell–treated patients |
topic | Letters to Blood |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281508/ https://www.ncbi.nlm.nih.gov/pubmed/35472242 http://dx.doi.org/10.1182/blood.2022016166 |
work_keys_str_mv | AT ohbernicelingzhi enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT tannicole enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT dealwisruklanthi enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT kunasegarankamini enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT chenzhiwei enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT poonmichelle enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT chanesther enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT lowjennygh enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT yeohallenengjuh enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT bertolettiantonio enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients AT lebertnina enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients |